← Leaderboards
April M. Weissmiller
Middle Tennessee State University
$1,192,251
Attributed
$1,192,251
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $681.1K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,192,251 · 4
By mechanism
R15$929,651 · 2
R03$262,600 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsTranscription FactorGenesGene ExpressionGenome-WideOncoproteinsChromatinOncogenicProgramsGenetic TranscriptionTumorBindingBiologic CharacteristicImpairmentTranscriptome SequencingGenomic ApproachTranscriptomeGenetic ApproachPublishingCell LineAutomobile DrivingAcuteDiagnosisTumorigenesis
Grant awards (5)
The MYC-SWI/SNF connection in cancers defined by SMARCA4 mutations$549,836
R15 · FY2025 · CA · contact PI
Development of a novel dual inhibitor for treatment of MYCN-amplified neuroblastoma$131,300
R03 · FY2025 · CA · contact PI
Exposing the role of MYC in small cell carcinoma of the ovary hypercalcemic type$65,650
R03 · FY2024 · CA · contact PI
Exposing the role of MYC in small cell carcinoma of the ovary hypercalcemic type$65,650
R03 · FY2023 · CA · contact PI
Determining the significance of the N-MYC-WDR5 interaction in neuroblastoma.$379,815
R15 · FY2021 · CA · contact PI